Katy Beckermann, MD, PhD
Kathryn Beckermann, MD, PhD, is the Medical Director of GU Clinical Research at Tennessee Oncology. She is a GU medical oncologist specialized in treating kidney, bladder, prostate, and testicular cancer.
Articles by Katy Beckermann, MD, PhD
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Drs. Beckermann and Barata explore the implications of the negative findings of the CONTACT-03 trial on clinical practice.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
The challenges of patient management and access to care are explored in the sixth part of our RLT roundtable discussion.
The fifth segment of the RLT roundtable explores recent clinical trials, including the VISION study.
The fourth part of this roundtable delves into the VISION and PSMAfore studies and their implications.
The third part of this roundtable explores imaging interpretation and toxicity management.
An expert panel discusses the evolving landscape of radioligand therapy for prostate cancer.
The panel discusses the role of PSMA imaging in prostate cancer, theranostics, and radioligand therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.